TY - JOUR
T1 - An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision
T2 - a report of a National Kidney Foundation Working Group
AU - Nester, Carla M.
AU - Feldman, David L.
AU - Burwick, Richard
AU - Cataland, Spero
AU - Chaturvedi, Shruti
AU - Cook, H. Terence
AU - Cuker, Adam
AU - Dixon, Bradley P.
AU - Fakhouri, Fadi
AU - Hingorani, Sangeeta R.
AU - Java, Anuja
AU - van de Kar, Nicole C.A.J.
AU - Kavanagh, David
AU - Leung, Nelson
AU - Licht, Christoph
AU - Noris, Marina
AU - O'Shaughnessy, Michelle M.
AU - Parikh, Samir V.
AU - Peyandi, Flora
AU - Remuzzi, Giuseppe
AU - Smith, Richard J.H.
AU - Sperati, C. John
AU - Waldman, Meryl
AU - Walker, Patrick
AU - Vivarelli, Marina
N1 - Publisher Copyright:
© 2024 International Society of Nephrology
PY - 2024/9
Y1 - 2024/9
N2 - The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin–associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
AB - The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin–associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
KW - complement
KW - hemolytic uremic syndrome
KW - nomenclature
KW - thrombotic microangiopathy
UR - http://www.scopus.com/inward/record.url?scp=85201077190&partnerID=8YFLogxK
U2 - 10.1016/j.kint.2024.05.021
DO - 10.1016/j.kint.2024.05.021
M3 - Article
C2 - 39174192
AN - SCOPUS:85201077190
SN - 0085-2538
VL - 106
SP - 326
EP - 336
JO - Kidney International
JF - Kidney International
IS - 3
ER -